SOUTH SAN FRANCISCO, Calif. – Jan. 7, 2003 – AGY Therapeutics, Inc. today announced that Karoly Nikolich, Ph.D., the company's chief executive officer, will present at the JP Morgan H & 21st Annual Healthcare Conference on Thursday, January 9. His presentation will take place at 1:00 p.m. PST in the Elizabethan A & Room at The Westin St. Francis Hotel in San Francisco.

For additional information contact:
Karoly Nikolich, Ph.D.
Chief Executive Officer
AGY Therapeutics, Inc.

Kristin Nash
WeissCom Partners

About ImAGYne™
AGY Therapeutics' proprietary imAGYne™ platform defines the intra- and extra-cellular signaling pathways that underlie the pathological progression of central nervous system (CNS) diseases, so novel, high-quality targets can be carefully selected and functionally validated with the most valuable targets advanced into drug discovery and development. To date, AGY Therapeutics has identified and characterized a vast number of promising drug targets to treat or diagnose CNS diseases.

About AGY Therapeutics
AGY Therapeutics, Inc., a privately-held biotechnology company, is dedicated to discovering and developing novel treatments for central nervous system (CNS) diseases, including stroke, Alzheimer's disease, depression, brain tumors and obesity.

This news release contains forward-looking statements about future research and development efforts. These statements represent our judgment as of the date of this news release and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. In particular, we face risks and uncertainties that further research into these genes may not go forward as planned or that future scientific data on these genes may not provide supportive data for the diseases we are targeting.

About AGY l Research & Development l Investors & Partners l AGY News l Career Opportunities l Contact Us